Predictions for relapse of rheumatoid arthritis after discontinuation of biologics

Predictions for relapse of rheumatoid arthritis after discontinuation of biologics - Predictions for relapse of rheumatoid arthritis after discontinuation of biologics

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041633

Enrollment

160

Registered

2020-09-01

Start date

2020-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The following individuals who had blood samples stored in the laboratory of Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine with written informed consent: (1) healthy individuals, (2) patients with active rheumatoid arthritis who were untreated at the time of sample collection, (3) patients with rheumatoid arthritis who had achieved clinical remission under tocilizumab at the time of sample collection, and (4) patients with rheumatoid arthritis who had achieved clinical remission under tocilizumab at the time of sample collection and who had discontinued tocilizumab treatment within 12 months of sample collection.

Exclusion criteria

Exclusion criteria: Patients considered unsuitable on medical grounds by study sponsors.

Design outcomes

Primary

Measure	Time frame
Association between molecular remission status before tocilizumab discontinuation and relapse after discontinuation.	—

Countries

Japan

Contacts

Public ContactNobuhiko Kajio

Keio University School of Medicine Division of Rheumatology, Department of Internal Medicine

nobuhiko.kajio@keio.jp03-5363-3786

Outcome results